2020 |
Al-Omary MS, Sugito S, Boyle AJ, Sverdlov AL, Collins NJ, 'Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.', Hypertension, 75 1397-1408 (2020)
|
|
|
2020 |
Ngo DTM, Williams T, Horder S, Kritharides L, Vardy J, Mandaliya H, et al., 'Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab.', J Clin Med, 9 (2020)
|
|
|
2020 |
Diaz A, Sverdlov AL, Kelly B, Ngo DTM, Bates N, Garvey G, 'Nexus of cancer and cardiovascular disease for Australia's first peoples', Journal of Global Oncology, 2020 115-119 (2020) [C1]
|
|
|
2019 |
Murtha L, Morten M, Schuliga M, Mabotuwana N, Hardy S, Waters D, et al., 'The Role of Pathological Aging in Cardiac and Pulmonary Fibrosis', Aging and Disease, 10 419-428 (2019) [C1]
|
|
|
2019 |
McGee M, Sugito S, Sverdlov AL, 'Cardiovascular Outcomes in Indigenous Australians: A National Gap', HEART LUNG AND CIRCULATION, 28 825-826 (2019)
|
|
|
2019 |
Ezad S, Khan AA, Cheema H, Ashraf A, Ngo DTM, Sverdlov AL, Collins NJ, 'Ibrutinib-related atrial fibrillation: A single center Australian experience', Asia-Pacific Journal of Clinical Oncology, 15 e187-e190 (2019) [C1]
© 2019 John Wiley & Sons Australia, Ltd Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of ar... [more]
© 2019 John Wiley & Sons Australia, Ltd Background: Ibrutinib increases the risk of atrial fibrillation (AF) and is associated with bleeding tendencies. Reported rates of arrhythmia are variable in different studies. The aim of the current analysis was to evaluate the incidence of AF in a single-center cohort of patients. Methods: This analysis was conducted at Hunter New England Local Health District, Australia between April 1, 2015 and June 30, 2017. We included all consecutive patients commenced on ibrutinib for hematological malignancies. Patients with a history of paroxysmal AF were excluded. The primary end point was incidence of AF. Time to diagnosis and management were secondary outcomes of interest. Results: A total of 24 patients (age 73¿±¿9 years, males n¿=¿16 [67%]) were commenced on ibrutinib treatment during the study period with chronic lymphocytic leukemia (n¿=¿21, 88%) as the main indication. During a median follow-up of 12 months, four (17%) patients were diagnosed with AF with increasing age, duration of ibrutinib treatment as associations. The median time to AF diagnosis was 9 (interquartile range [IQR]: 7-18) months. All patients were managed with a rate control strategy with beta blockers as the preferred agents. Three (75%) patients were commenced on anticoagulation for stroke prevention. During a follow-up of 18 (IQR: 17-23) months following AF onset, one patient required hospitalization for AF. There were no bleeding complications reported. Conclusions: In conclusion, this series noted a higher incidence of AF than previously reported. Oncologists and cardiologists need to be aware of the increased risk of AF in patients receiving ibrutinib.
|
|
|
2019 |
Croft AJ, Ngo DTM, Sverdlov AL, 'Anthracycline-Induced Cardiotoxicity: Time to Focus on Cardioprotection Again', Heart Lung and Circulation, 28 1454-1456 (2019) [C1]
|
|
|
2019 |
Ngo DTM, Sverdlov AL, Karki S, Macartney-Coxson D, Stubbs RS, Farb MG, et al., 'Oxidative modifications of mitochondrial complex ii are associated with insulin resistance of visceral fat in obesity', American Journal of Physiology - Endocrinology and Metabolism, 316 E168-E177 (2019) [C1]
© 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been ... [more]
© 2019 the American Physiological Society. Obesity, particularly visceral adiposity, has been linked to mitochondrial dysfunction and increased oxidative stress, which have been suggested as mechanisms of insulin resistance. The mechanism(s) behind this remains incompletely understood. In this study, we hypothesized that mitochondrial complex II dysfunction plays a role in impaired insulin sensitivity in visceral adipose tissue of subjects with obesity. We obtained subcutaneous and visceral adipose tissue biopsies from 43 subjects with obesity (body mass index = 30 kg/m 2 ) during planned bariatric surgery. Compared with subcutaneous adipose tissue, visceral adipose tissue exhibited decreased complex II activity, which was restored with the reducing agent dithiothreitol (5 mM) (P < 0.01). A biotin switch assay identified that cysteine oxidative posttranslational modifications (OPTM) in complex II subunit A (succinate dehydrogenase A) were increased in visceral vs. subcutaneous fat (P < 0.05). Insulin treatment (100 nM) stimulated complex II activity in subcutaneous fat (P < 0.05). In contrast, insulin treatment of visceral fat led to a decrease in complex II activity (P < 0.01), which was restored with addition of the mitochondria-specific oxidant scavenger mito-TEMPO (10 µ M). In a cohort of 10 subjects with severe obesity, surgical weight loss decreased OPTM and restored complex II activity, exclusively in the visceral depot. Mitochondrial complex II may be an unrecognized and novel mediator of insulin resistance associated with visceral adiposity. The activity of complex II is improved by weight loss, which may contribute to metabolic improvements associated with bariatric surgery.
|
|
|
2019 |
Figtree GA, Ngo DTM, Bubb KJ, 'Testosterone to estradiol ratio and plaque inflammation: Mechanistic insights and biomarker potential?', Cardiovascular Research, 115 255-257 (2019) [C1]
|
|
|
2018 |
Luptak I, Sverdlov AL, Panagia M, Qin F, Pimentel DR, Croteau D, et al., 'Decreased ATP production and myocardial contractile reserve in metabolic heart disease.', Journal of molecular and cellular cardiology, 116 106-114 (2018) [C1]
|
|
|
2018 |
Efird JT, Jindal C, Kiser AC, Akhter SA, Crane PB, Kypson AP, et al., 'Increased risk of atrial fibrillation among patients undergoing coronary artery bypass graft surgery while receiving nitrates and antiplatelet agents', Journal of International Medical Research, 46 3183-3194 (2018) [C1]
© The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more f... [more]
© The Author(s) 2018. Background: Postoperative atrial fibrillation (POAF) is a frequent complication of coronary artery bypass graft (CABG) surgery. This arrhythmia occurs more frequently among patients who receive perioperative inotropic therapy (PINOT). Administration of nitrates with antiplatelet agents reduces the conversion rate of cyclic guanosine monophosphate to guanosine monophosphate. This process is associated with increased concentrations of free radicals, catecholamines, and blood plasma volume. We hypothesized that patients undergoing CABG surgery who receive PINOT may be more susceptible to POAF when nitrates are administered with antiplatelet agents. Methods: Clinical records were examined from a prospectively maintained cohort of 4,124 patients undergoing primary isolated CABG surgery to identify POAF-associated factors. Results: POAF risk was increased among patients receiving PINOT, and the greatest effect was observed when nitrates were administered with antiplatelet therapy. Adjustment for comorbidities did not substantively change the study results. Conclusions: Administration of nitrates with certain antiplatelet agents was associated with an increased POAF risk among patients undergoing CABG surgery. Additional studies are needed to determine whether preventive strategies such as administration of antioxidants will reduce this risk.
|
|
|
2018 |
Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, et al., 'Nitrosative Stress as a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome.', JACC. Basic to translational science, 3 213-226 (2018)
|
|
|
2017 |
Karki S, Ngo DTM, Farb MG, Park SY, Saggese SM, Hamburg NM, et al., 'WNT5A regulates adipose tissue angiogenesis via antiangiogenic VEGF-A(165)b in obese humans', AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 313 H200-H206 (2017)
|
|
|
2017 |
Amarasekera AT, Assadi-Khansari B, Liu S, Black M, Dymmott G, Rogers NM, et al., 'Vitamin D supplementation lowers thrombospondin-1 levels and blood pressure in healthy adults', PLOS ONE, 12 (2017)
|
|
|
2017 |
Sverdlov AL, Ngo DTM, 'Response to the letter to editor: Galectin-3 and atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 229 2-2 (2017)
|
|
|
2017 |
Canavese M, Ngo DTM, Maddern GJ, Hardingham JE, Price TJ, Hauben E, 'Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer', INTERNATIONAL JOURNAL OF CANCER, 140 2183-2191 (2017)
|
|
|
2016 |
Miller EJ, Calamaras T, Elezaby A, Sverdlov A, Qin F, Luptak I, et al., 'Partial Liver Kinase B1 (LKB1) Deficiency Promotes Diastolic Dysfunction, De Novo Systolic Dysfunction, Apoptosis, and Mitochondrial Dysfunction With Dietary Metabolic Challenge', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)
|
|
|
2016 |
Sverdlov AL, Figtree GA, Horowitz JD, Ngo DTM, 'Interplay between Oxidative Stress and Inflammation in Cardiometabolic Syndrome', MEDIATORS OF INFLAMMATION, 2016 (2016)
|
|
|
2016 |
Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, et al., 'Mitochondrial Reactive Oxygen Species Mediate Cardiac Structural, Functional, and Mitochondrial Consequences of Diet-Induced Metabolic Heart Disease', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 5 (2016)
|
|
|
2016 |
Procter NEK, Ball J, Ngo DTM, Isenberg JS, Hylek EM, Chirkov YY, et al., 'Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation', JOURNAL OF GERIATRIC CARDIOLOGY, 13 202-208 (2016)
|
|
|
2016 |
Chen D, Procter N, Goh V, Liu S, Chua SJ, Assadi-Khansari B, et al., 'New onset atrial fibrillation is associated with elevated galectin-3 levels', International Journal of Cardiology, 223 48-49 (2016) [C1]
|
|
|
2016 |
Amarasekera AT, Sverdlov AL, Horowitz JD, Ngo DT, 'Elevated parathyroid hormone predicts high asymmetric dimethylarginine (ADMA) concentrations in obese diabetic patients', Diabetes and Metabolism, 42 378-381 (2016) [C1]
|
|
|
2016 |
Procter NEK, Ball J, Ngo DTM, Chirkov YY, Isenberg JS, Hylek EM, et al., 'Platelet hyperaggregability in patients with atrial fibrillation Evidence of a background proinflammatory milieu', HERZ, 41 57-62 (2016)
|
|
|
2015 |
Sverdlov AL, Elezaby A, Behring JB, Bachschmid MM, Luptak I, Tu VH, et al., 'High fat, high sucrose diet causes cardiac mitochondrial dysfunction due in part to oxidative post-translational modification of mitochondrial complex II', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 78 165-173 (2015) [C1]
|
|
|
2015 |
Yao C, Behring JB, Shao D, Sverdlov AL, Whelan SA, Elezaby A, et al., 'Overexpression of Catalase Diminishes Oxidative Cysteine Modifications of Cardiac Proteins', PLOS ONE, 10 (2015) [C1]
|
|
|
2015 |
Taniguchi Y, Takahashi Y, Toba T, Yamada S, Yokoi K, Kobayashi S, et al., 'Poster Session 1: Sunday 3 May 2015, 08:30-18:00 * Room: Poster Area', European Heart Journal - Cardiovascular Imaging, 16 i11-i28 (2015)
|
|
|
2015 |
Horowitz JD, Chong C-R, Ngo DT, Sverdlov AL, 'Effects of acute hyperglycaemia on cardiovascular homeostasis: does a spoonful of sugar make the flow-mediated dilatation go down?', JOURNAL OF THORACIC DISEASE, 7 E607-E611 (2015)
|
|
|
2015 |
Fuster JJ, Zuriaga MA, Doan T-MN, Farb MG, Aprahamian T, Yamaguchi TP, et al., 'Noncanonical Wnt Signaling Promotes Obesity-Induced Adipose Tissue Inflammation and Metabolic Dysfunction Independent of Adipose Tissue Expansion', DIABETES, 64 1235-1248 (2015)
|
|
|
2015 |
Procter NEK, Ball J, Liu S, Hurst N, Nooney VB, Goh V, et al., 'Impaired platelet nitric oxide response in patients with new onset atrial fibrillation', INTERNATIONAL JOURNAL OF CARDIOLOGY, 179 160-165 (2015)
|
|
|
2015 |
Karki S, Farb MG, Ngo DTM, Myers S, Puri V, Hamburg NM, et al., 'Forkhead Box O-1 Modulation Improves Endothelial Insulin Resistance in Human Obesity', ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 35 1498-1506 (2015)
|
|
|
2015 |
Liu S, Ngo DTM, Chong C-R, Amarasekera AT, Procter NEK, Licari G, et al., 'Suppression of neutrophil superoxide generation by BNP is attenuated in acute heart failure: a case for 'BNP resistance'', EUROPEAN JOURNAL OF HEART FAILURE, 17 475-483 (2015)
|
|
|
2015 |
Procter NEK, Ball J, Heresztyn T, Nooney VB, Liu S, Chong C-R, et al., 'Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 5 101-109 (2015) |
|
|
2015 |
Chong C-R, Liu S, Licari G, Heresztyn T, Chirkov YY, Ngo DT, Horowitz JD, 'Reversal of hyperglycemia: effects on nitric oxide signaling.', Am J Med, 128 427-430 (2015)
|
|
|
2015 |
Ngo DT, Gokce N, 'Epicardial adipose tissue: a benign consequence of obesity?', Circ Cardiovasc Imaging, 8 (2015)
|
|
|
2015 |
Elezaby A, Sverdlov AL, Tu VH, Soni K, Luptak I, Qin F, et al., 'Mitochondrial remodeling in mice with cardiomyocyte-specific lipid overload', JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 79 275-283 (2015) [C1]
|
|
|
2014 |
Procter NEK, Chong C-R, Sverdlov AL, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of Platelet Nitric Oxide Signaling: Pathogenesis, Clinical Implications, and Therapeutics', SEMINARS IN THROMBOSIS AND HEMOSTASIS, 40 660-668 (2014)
|
|
|
2014 |
Chong C-R, Chan WPA, Nguyen TH, Liu S, Procter NEK, Ngo DT, et al., 'Thioredoxin-Interacting Protein: Pathophysiology and Emerging Pharmacotherapeutics in Cardiovascular Disease and Diabetes', CARDIOVASCULAR DRUGS AND THERAPY, 28 347-360 (2014)
|
|
|
2014 |
Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M, et al., 'Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis', JOURNAL OF NUCLEAR CARDIOLOGY, 21 925-939 (2014)
|
|
|
2014 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Horowitz JD, 'Aging of the Nitric Oxide System: Are We as Old as Our NO?', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 3 (2014)
|
|
|
2014 |
Karki S, Ngo DTM, Bigornia SJ, Farb MG, Gokce N, 'Insulin resistance: a key therapeutic target for cardiovascular risk reduction in obese patients?', EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 9 93-95 (2014)
|
|
|
2014 |
Ngo DTM, Farb MG, Kikuchi R, Karki S, Tiwari S, Bigornia SJ, et al., 'Antiangiogenic Actions of Vascular Endothelial Growth Factor-A(165)b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity', CIRCULATION, 130 1072-1080 (2014)
|
|
|
2014 |
Kikuchi R, Nakamura K, MacLauchlan S, Doan T-MN, Shimizu I, Fuster JJ, et al., 'An antiangiogenic isoform of VEGF-A contributes to impaired vascularization in peripheral artery disease', NATURE MEDICINE, 20 1464-1471 (2014)
|
|
|
2014 |
Liu S, Ngo DTM, Stewart S, Horowitz JD, Chirkov YY, 'B-Type natriuretic peptide suppression of neutrophil superoxide generation: mechanistic studies in normal subjects', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 41 739-743 (2014)
|
|
|
2014 |
Farb MG, Tiwari S, Karki S, Ngo DTM, Carmine B, Hess DT, et al., 'Cyclooxygenase Inhibition Improves Endothelial Vasomotor Dysfunction of Visceral Adipose Arterioles in Human Obesity', OBESITY, 22 349-355 (2014)
|
|
|
2013 |
Chan WPA, Ngo DT, Sverdlov AL, Rajendran S, Stafford I, Heresztyn T, et al., 'Premature Aging of Cardiovascular/Platelet Function in Polycystic Ovarian Syndrome', AMERICAN JOURNAL OF MEDICINE, 126 (2013) [C1]
|
|
|
2013 |
Maher AR, Arif S, Madhani M, Abozguia K, Ahmed I, Fernandez BO, et al., 'Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite', BRITISH JOURNAL OF PHARMACOLOGY, 169 659-670 (2013) [C1]
|
|
|
2013 |
Sverdlov AL, Chan WPA, Procter NEK, Chirkov YY, Ngo DTM, Horowitz JD, 'Reciprocal regulation of NO signaling and TXNIP expression in humans: Impact of aging and ramipril therapy', INTERNATIONAL JOURNAL OF CARDIOLOGY, 168 4624-4630 (2013)
|
|
|
2013 |
Ngo DTM, Horowitz JD, Sverdlov AL, 'Heart Failure A Corin-Deficient State?', HYPERTENSION, 61 284-285 (2013)
|
|
|
2013 |
Nguyen TH, Neil CJ, Sverdlov AL, Ngo DT, Chan WP, Heresztyn T, et al., 'Enhanced NO Signaling in Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain?', CARDIOVASCULAR DRUGS AND THERAPY, 27 541-547 (2013)
|
|
|
2013 |
Dautov RF, Ngo DTM, Licari G, Liu S, Sverdlov AL, Ritchie RH, et al., 'The nitric oxide redox sibling nitroxyl partially circumvents impairment of platelet nitric oxide responsiveness', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 35 72-78 (2013)
|
|
|
2012 |
Neil C, Thanh HN, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al., 'Slowly resolving global myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted cardiac MRI', HEART, 98 1278-1284 (2012)
|
|
|
2012 |
Ngo DT, Sverdlov AL, Horowitz JD, 'Prevention of aortic valve stenosis: A realistic therapeutic target?', PHARMACOLOGY & THERAPEUTICS, 135 78-93 (2012)
|
|
|
2012 |
Sverdlov AL, Ngo DT, Horowitz JD, 'Redefining the natural history of calcific aortic stenosis: lessons from Laennec', JOURNAL OF INTERNAL MEDICINE, 271 569-572 (2012)
|
|
|
2012 |
Sverdlov AL, Ngo DTM, Chan WPA, Chirkov YY, Gersh BJ, McNeil JJ, Horowitz JD, 'Determinants of aortic sclerosis progression: Implications regarding impairment of nitric oxide signalling and potential therapeutics', European Heart Journal, 33 2419-2425 (2012) [C1]
|
|
|
2012 |
Neil CJ, Nguyen TH, Sverdlov AL, Chirkov YY, Chong C-R, Stansborough J, et al., 'Can we make sense of takotsubo cardiomyopathy? An update on pathogenesis, diagnosis and natural history', EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 10 215-221 (2012)
|
|
|
2012 |
Sverdlov AL, Ngo DTM, Horowitz JD, 'Pathogenesis of aortic sclerosis: association with low BMI, tissue nitric oxide resistance, but not systemic inflammatory activation', AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE, 2 43-49 (2012)
|
|
|
2011 |
Ngo DTM, Stafford I, Sverdlov AL, Qi W, Wuttke RD, Zhang Y, et al., 'Ramipril retards development of aortic valve stenosis in a rabbit model: Mechanistic considerations', British Journal of Pharmacology, 162 722-732 (2011) [C1]
|
|
|
2011 |
Sverdlov AL, Ngo DT, Chapman MJ, Ali OA, Chirkov YY, Horowitz JD, 'Pathogenesis of aortic stenosis: not just a matter of wear and tear.', Am J Cardiovasc Dis, 1 185-199 (2011)
|
|
|
2011 |
Nguyen TH, Neil CJ, Sverdlov AL, Mahadavan G, Chirkov YY, Kucia AM, et al., 'N-Terminal Pro-Brain Natriuretic Protein Levels in Takotsubo Cardiomyopathy', AMERICAN JOURNAL OF CARDIOLOGY, 108 1316-1321 (2011)
|
|
|
2011 |
Ling L-H, Chik W, Averbuj P, Pati PK, Sverdlov AL, Ngo DTM, et al., 'Effects of Aging, Renal Dysfunction, Left Ventricular Systolic Impairment, and Weight on Steady State Pharmacokinetics of Perhexiline', THERAPEUTIC DRUG MONITORING, 33 251-256 (2011)
|
|
|
2011 |
Nightingale AK, Sverdlov AL, Rajendran S, Mishra K, Heresztyn T, Ngo DTM, Horowitz JD, 'Lack of association between aortic sclerosis and left ventricular hypertrophy in elderly subjects', INTERNATIONAL JOURNAL OF CARDIOLOGY, 150 33-38 (2011)
|
|
|
2011 |
Sverdlov AL, Ngo DTM, Nightingale AK, Rajendran S, Mishra K, Heresztyn T, et al., 'The endogenous NOS inhibitor asymmetric dimethylarginine (ADMA) predicts LV mass independent of afterload', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 41-46 (2011)
|
|
|
2011 |
Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, et al., 'Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 25 326-330 (2011)
|
|
|
2010 |
Horowitz JD, Chirkov YY, Kennedy JA, Sverdlov AL, 'Modulation of myocardial metabolism: An emerging therapeutic principle', Current Opinion in Cardiology, 25 329-334 (2010)
|
|
|
2010 |
Ngo DT, Sverdlov AL, McNeil JJ, Horowitz JD, 'Does Vitamin D Modulate Asymmetric Dimethylarginine and C-Reactive Protein Concentrations?', AMERICAN JOURNAL OF MEDICINE, 123 335-341 (2010)
|
|
|
2010 |
Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD, 'Hydralazine does not Ameliorate Nitric Oxide Resistance in Chronic Heart Failure', CARDIOVASCULAR DRUGS AND THERAPY, 24 131-137 (2010)
|
|
|
2009 |
Ngo DTM, Sverdlov AL, McNeil JJ, Horowitz JD, 'Correlates of arterial stiffness in an ageing population: Role of asymmetric dimethylarginine', PHARMACOLOGICAL RESEARCH, 60 503-507 (2009)
|
|
|
2009 |
Ngo DTM, Sverdlov AL, Willoughby SR, Nightingale AK, Chirkov YY, McNeil JJ, Horowitz JD, 'Determinants of Occurrence of Aortic Sclerosis in an Aging Population', JACC-CARDIOVASCULAR IMAGING, 2 919-927 (2009)
|
|
|
2008 |
Sverdlov AL, Taylor K, Elkington AG, Zeitz CJ, Beltrame JF, 'Cardiac magnetic resonance imaging identifies the elusive perivalvular abscess', CIRCULATION, 118 E1-E3 (2008)
|
|
|
2008 |
Ngo DTM, Stafford I, Kelly DJ, Sverdlov AL, Wuttke RD, Weedon H, et al., 'Vitamin D(2) supplementation induces the development of aortic stenosis in rabbits: Interactions with endothelial function and thioredoxin-interacting protein', EUROPEAN JOURNAL OF PHARMACOLOGY, 590 290-296 (2008)
|
|
|
2008 |
Chan WPA, Sverdlov AL, Horowitz JD, 'Management of the metabolic syndrome in cardiovascular disease', Current Treatment Options in Cardiovascular Medicine, 10 27-38 (2008)
The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, ... [more]
The main components of the metabolic syndrome (MS) are abdominal obesity, atherogenic dyslipidemia, raised blood pressure, insulin resistance with or without glucose intolerance, and proinflammatory and prothrombotic states. The clustering of these metabolic risk factors significantly increases the risk of type 2 diabetes and promotes vascular endothelial dysfunction, inflammation, and increased oxidative stress. The net result is an increase in the risk of atherosclerotic cardiovascular disease. Therefore, management of MS is of utmost importance, especially considering its rapidly increasing prevalence in a population with rising obesity rates and its significant cardiovascular implications. The primary management of this syndrome involves the correction of the underlying risk factors - obesity, physical inactivity, and an atherogenic diet - with lifestyle modifications including increased physical activity and dietary modification. Smoking cessation also should be encouraged. However, pharmacologic therapies are often required to address cardiovascular risk factors. These agents can be categorized broadly into 1) anorectic agents, 2) insulin-sensitizing agents, 3) statins, and 4) renin-angiotensin system antagonists. Emerging therapies include adipokines, endocannabinoid inhibitors, and metabolic modulators, such as perhexiline and trimetazidine. To date, these therapies have not been shown to normalize the metabolic and cardiovascular burden of MS, and there still is no single therapeutic agent for its management. Copyright © 2008 by Current Medicine Group LLC.
|
|
|
2007 |
Ngo DTM, Heresztyn T, Mishra K, Marwick TH, Horowitz JD, 'Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA)', NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 16 197-201 (2007)
|
|
|
2004 |
Ngo DTM, Wuttke RD, Turner S, Marwick TH, Horowitz JD, 'Quantitative assessment of aortic sclerosis using ultrasonic backscatter', JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 17 1123-1130 (2004)
|
|
|
1973 |
McLaren J, Ngo DT, Olivera BM, 'Pyridine nucleotide metabolism in Escherichia coli. 3. Biosynthesis from alternative precursors in vivo.', The Journal of biological chemistry, 248 5144-5149 (1973) |
|
|